A simplified co-culture reveals altered cardiotoxic responses to doxorubicin in hPSC-derived cardiomyocytes in the presence of endothelial cells

Read full text
Authors: Marcella Brescia, James Gallant, Andrea Chatrian, Paul Keselman, Elsa Sorman Paulsson, Mervyn P.H. Mol, Rickard Sjögren, Karine Raymond, Valeria V. Orlova, Kalpana Barnes, Richard Wales, Jonas Austerjost
+4 more Michael W. Olszowy, C. Mummery, Berend J. van Meer, Richard P. Davis
Cited by: 2
References: 42

Abstract

Cardiotoxicity is a significant challenge in cancer therapies, particularly with doxorubicin, a widely used anthracycline. More predictive in vitro models are needed to understand doxorubicin-induced cardiac damage and patient-specific responses. Here, human pluripotent stem cell (hPSC)-derived cardiomyocytes (hPSC-CMs), cardiac fibroblasts (hPSC-cFBs), and endothelial cells (hPSC-ECs) were cultured in mono- or multi-cell-type formats and repeatedly treated with doxorubicin to mimic cumulative clinical exposure. A machine learning-based tool enabled continuous quantification of the early toxicity marker caspase-3/7 and accurately identified hPSC-CMs within mixed cultures. Notably, hPSC-ECs were more sensitive to doxorubicin than hPSC-CMs or hPSC-cFBs, with nitric oxide signaling contributing to the elevated cardiomyocyte toxicity observed in co-culture. These results question the conventional in vitro focus on cardiomyocytes regarding drug-induced cardiac damage, highlighting the interplay among different cardiac cell types in mediating the toxic effects of doxorubicin. Furthermore, the work demonstrates the potential of AI-based tools to provide scalable strategies for assessing drug-induced cardiotoxicity.

Fields of Study & Subjects

Chemotherapy-induced cardiotoxicity and mitigation Cardiac electrophysiology and arrhythmias Congenital heart defects research

Publication details

Journal / source
Stem Cell Reports
Publisher
Elsevier BV
Volume
21
Issue
3
Pages
102816–102816
Publication date
12 February 2026
Language
EN